GN
GNLX.US Genelux Corporation Common Stock
- Market cap
- USD 84.4M
- P/E
- -
- P/B
- 5.31x
- ROE
- -206.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GNLX.US undervalued?
Graham numberThe Graham number of Genelux Corporation Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genelux Corporation Common Stock fundamental analysis
No fundamental analysis for Genelux Corporation Common Stock yet.
Genelux Corporation Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive libr…
Full company profileGenelux Corporation Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genelux Corporation Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 11.1M | 170K | 8.00K | 8.00K | 0.00 |
| Gross Profit | -477K | -658K | -895K | 10.1M | -848K | -895K | -566K | - |
| Operating Income | -10.9M | -12.4M | -14.6M | -3.01M | -24.2M | -31.7M | -33.2M | -36.0M |
| EBITDA | -10.4M | -11.8M | -13.7M | -1.73M | -26.5M | -29.0M | -31.6M | -33.0M |
| Net Income | -11.6M | -14.9M | -17.8M | -5.21M | -28.3M | -29.9M | -32.1M | -33.2M |
| EPS | -0.49 | -0.63 | -0.75 | -0.21 | -1.16 | -0.95 | -0.86 | -0.74 |
| Balance Sheet | ||||||||
| Total Assets | 3.28M | 14.0M | 8.13M | 5.53M | 27.9M | 34.7M | 19.0M | 26.2M |
| Total Liabilities | 28.1M | 36.7M | 41.2M | 41.3M | 8.42M | 8.44M | 7.48M | 10.1M |
| Shareholders' Equity | -24.8M | -22.7M | -33.1M | -35.8M | 19.5M | 26.3M | 11.5M | 16.1M |
| Cash & Short-term Investments | 425K | 11.4M | 4.50M | 397K | 23.2M | 30.9M | 14.6M | 18.7M |
| Total Debt | 18.0M | 26.1M | 25.3M | 26.4M | 2.52M | 1.87M | 1.69M | 2.42M |
| Cash Flow | ||||||||
| Operating Cash Flow | -7.22M | -7.21M | -6.59M | -3.57M | -20.3M | -21.2M | -25.3M | -25.0M |
| Capital Expenditure | 1.77M | 20.0K | 49.0K | 49.0K | 1.03M | 381K | 1.10M | 4.91M |
| Free Cash Flow | -8.99M | -7.23M | -6.59M | -3.62M | -21.3M | -21.6M | -26.4M | -29.9M |
| Ratios | ||||||||
| ROE | - | - | - | - | -145.3% | -113.7% | -278.5% | -206.0% |
| ROA | -354.5% | -106.1% | -219.0% | -94.1% | -101.4% | -86.0% | -168.9% | -126.7% |
| Net Profit Margin | - | - | - | -47.0% | -16,645.3% | -373,362.5% | -401,812.5% | - |
| Debt to Equity | - | - | - | - | 0.13x | 0.07x | 0.15x | 0.15x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genelux Corporation Common Stock dividends
Genelux Corporation Common Stock has not paid dividends in the last 7 fiscal years.
Who owns Genelux Corporation Common Stock
- Insiders 12.20%
- Institutions 32.06%
- Public & others 55.74%
- Shares outstanding 45.2M
- Free float 36.5M
Top funds holding GNLX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.19M | 2.67% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 207K | 0.46% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 125K | 0.28% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 66.2K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 64.0K | 0.14% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 34.3K | 0.08% | +18.81% | Jun 2026 |
| Vanguard U.S. Eq Idx £ Acc | 16.0K | 0.04% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 8.20K | 0.02% | -11.84% | Sep 2026 |
| Victory Extended Market Index | 4.43K | 0.01% | -4.28% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 3.92K | 0.01% | -85.19% | Aug 2026 |
| Knights of Columbus U.S. All Cap Idx I | 227.00 | 0.00% | -0.44% | Sep 2026 |
Top institutions holding GNLX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| WOODWARD DIVERSIFIED CAPITAL, LLC | 2.38M | 5.32% | +5.16% | Sep 2026 |
| Vanguard Capital Management, LLC | 1.68M | 3.75% | -1.05% | Jun 2026 |
| Bleichroeder LP | 1.38M | 3.09% | 0.00% | Jun 2026 |
| BlackRock Inc | 440K | 0.98% | +8.31% | Jun 2026 |
| Geode Capital Management, LLC | 439K | 0.98% | -3.21% | Jun 2026 |
| CM Management, LLC | 400K | 0.89% | +60.00% | Jun 2026 |
| Bank of America Corp | 329K | 0.74% | +1.52% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 236K | 0.53% | -6.07% | Jun 2026 |
| F.L.Putnam Investment Management | 231K | 0.52% | -17.62% | Jun 2026 |
| Global Retirement Partners, LLC. | 228K | 0.51% | +4.96% | Jun 2026 |
| LPL Financial Corp | 158K | 0.35% | +13.53% | Jun 2026 |
| State Street Corp | 146K | 0.33% | 0.00% | Jun 2026 |
| Provident Wealth Management, LLC | 145K | 0.32% | -6.91% | Jun 2026 |
| LifeSteps Financial, Inc. | 122K | 0.27% | +2.61% | Jun 2026 |
| Advisor Group Holdings, Inc. | 122K | 0.27% | +2.48% | Jun 2026 |
| Renaissance Technologies Corp | 105K | 0.24% | +762.53% | Jun 2026 |
| Northern Trust Corp | 89.3K | 0.20% | -45.71% | Jun 2026 |
| Citadel Advisors Llc | 85.5K | 0.19% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 83.5K | 0.19% | -5.12% | Jun 2026 |
| Steel Peak Wealth Management LLC | 75.9K | 0.17% | +24.63% | Jun 2026 |
Genelux Corporation Common Stock company profile
- Company name
- Genelux Corporation Common Stock
- Ticker
- GNLX.US
- Exchange
- USA Stocks
- Listed since
- Jan 26, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 25
- Fiscal year end
- December
- Address
- 2625 Townsgate Road, Westlake Village, CA, United States, 91361
- Phone
- 805 267 9889
- Website
- genelux.com
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Genelux Corporation Common Stock management
7- Mr. Thomas D. Zindrick J.D.Chairman, CEO & President · born 1960
- Mr. Matthew Pulisic M.B.A.CFO and Principal Financial & Accounting Officer · born 1984
- Dr. Joseph Cappello Ph.D.Chief Technical Officer · born 1957
- Dr. Yong Yu Ph.D.Chief Scientific Officer · born 1972
- Mr. Eric Groen J.D.General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development · born 1971
- Mr. Ralph Smalling B.Sc.VP & Head of Regulatory Affairs · born 1955
- Dr. Jason B. Litten M.D.Chief Medical Officer · born 1974